表紙
市場調查報告書

原癌基因酪胺酸蛋白激酶 ROS:開發中產品分析

Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 371028
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
原癌基因酪胺酸蛋白激酶 ROS:開發中產品分析 Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 90 Pages
簡介

本報告提供以原癌基因酪胺酸蛋白激酶為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊ROS。

簡介

  • 調查範圍

原癌基因酪胺酸蛋白激酶 ROS 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Arrien Pharmaceuticals, LLC
  • 第一三共
  • Ignyta, Inc.
  • Pfizer Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2309TDB

Summary

According to the recently published report 'Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2020'; Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene. It activates several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. It mediates the phosphorylation of PTPN11, an activator of this pathway. It phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. It mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology.

The report 'Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2020' outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 3 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology and Genetic Disorders which include indications Non-Small Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Neuroblastoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Non-Hodgkin Lymphoma, Breast Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Gallbladder Cancer, Head And Neck Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, Angiosarcoma, Astrocytoma, Brain Cancer, Clear Cell Squamous Cell Carcinoma, Esophageal Cancer, Fibrosarcoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Sensitive Breast Cancer, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liver Cancer, Lymphoma, Malignant Neoplasms, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Carcinoma, Osteolytic Bone Metastasis, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Synovial Sarcoma, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
  • The report reviews Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

TABLE OF CONTENTS

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Overview
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • AnHeart Therapeutics Inc
    • Ascentage Pharma Group International
    • Eli Lilly and Co
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc
    • Turning Point Therapeutics Inc
    • Xcovery Holding Company LLC
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Drug Profiles
    • APG-2449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-6051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ensartinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entrectinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lorlatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • repotrectinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WY-135 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Dormant Products
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 21, 2020: Chugai obtains approval for additional indication of Rozlytrek for ROS1 fusion-positive Non-Small Cell Lung Cancer
      • Jan 15, 2020: Crizotinib in NSCLC with a MET exon 14 alteration
      • Dec 26, 2019: Chugai obtains approval for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive Lung Cancer
      • Dec 13, 2019: Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
      • Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
      • Nov 08, 2019: Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
      • Oct 30, 2019: European Society for Medical Oncology: Phase I/II study results with Lorlatinib in ROS1-positive advanced NSCLC
      • Oct 29, 2019: Vanderbilt Oncologists publish results of first study to demonstrate clinical utility of resolution liquid biopsy assay to monitor response and resistance to Ensartinib
      • Oct 17, 2019: The Lancet Respiratory Medicine published study shows Ensartinib holds promise as a new treatment option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)
      • Sep 25, 2019: Preclincal results of Baoyuan's next-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications
      • Sep 06, 2019: Chugai files for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive NSCLC
      • Sep 04, 2019: Chugai launches Rozlytrek, an Anticancer Agent for the treatment of NTRK Fusion-Positive Solid Tumors
      • Sep 03, 2019: Turning Point Therapeutics announces updated interim clinical data of Repotrectinib
      • Aug 21, 2019: ROZLYTREK (entrectinib), FDA approved for hard-to-treat NTRK fusion-positive tumors, available at Biologics by McKesson
      • Aug 16, 2019: FDA approves Roche Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by AnHeart Therapeutics Inc, H1 2020
  • Pipeline by Ascentage Pharma Group International, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Pipeline by Pfizer Inc, H1 2020
  • Pipeline by Turning Point Therapeutics Inc, H1 2020
  • Pipeline by Xcovery Holding Company LLC, H1 2020
  • Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020